Brought to you by 
Molecular Targeting licenses Draximage imaging agent
13 Jul 1999
Executive Summary
Draxis Health's radiopharm subsidiary Draximage will collaborate with Molecular Targeting Technology (several biotechnologies, primarily in cardiovascular applications) to develop agents for hot spot cardiac nuclear imaging.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Molecular Targeting licenses Draximage imaging agent
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice